BLI Banque de Luxembourg Investments Has $38.74 Million Holdings in Waters Corporation $WAT

BLI Banque de Luxembourg Investments decreased its position in shares of Waters Corporation (NYSE:WAT) by 32.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 100,920 shares of the medical instruments supplier’s stock after selling 48,480 shares during the period. Waters comprises 1.1% of BLI Banque de Luxembourg Investments’ holdings, making the stock its 24th largest holding. BLI Banque de Luxembourg Investments’ holdings in Waters were worth $38,740,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Mondrian Investment Partners LTD bought a new position in Waters in the 3rd quarter valued at approximately $1,397,000. SG Americas Securities LLC lifted its stake in Waters by 543.8% in the 4th quarter. SG Americas Securities LLC now owns 37,244 shares of the medical instruments supplier’s stock valued at $14,146,000 after purchasing an additional 31,459 shares during the last quarter. Mackenzie Financial Corp lifted its stake in Waters by 12.2% in the 3rd quarter. Mackenzie Financial Corp now owns 231,852 shares of the medical instruments supplier’s stock valued at $69,512,000 after purchasing an additional 25,182 shares during the last quarter. Vanguard Group Inc. lifted its stake in Waters by 3.3% in the 3rd quarter. Vanguard Group Inc. now owns 7,656,891 shares of the medical instruments supplier’s stock valued at $2,295,612,000 after purchasing an additional 246,128 shares during the last quarter. Finally, Alberta Investment Management Corp bought a new position in Waters in the 3rd quarter valued at approximately $4,677,000. Institutional investors and hedge funds own 94.01% of the company’s stock.

Waters Price Performance

WAT stock opened at $363.27 on Tuesday. The company has a fifty day moving average price of $332.29 and a 200-day moving average price of $350.61. The company has a market capitalization of $35.67 billion, a P/E ratio of 46.16, a PEG ratio of 2.21 and a beta of 1.21. Waters Corporation has a 52-week low of $275.05 and a 52-week high of $414.15. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.13 and a current ratio of 1.79.

Waters (NYSE:WAT) last announced its earnings results on Tuesday, May 5th. The medical instruments supplier reported $2.70 earnings per share for the quarter, topping analysts’ consensus estimates of $2.31 by $0.39. Waters had a net margin of 11.91% and a return on equity of 15.60%. The business had revenue of $1.27 billion during the quarter, compared to the consensus estimate of $1.20 billion. During the same quarter last year, the firm earned $2.25 earnings per share. Waters’s quarterly revenue was up 91.4% on a year-over-year basis. Waters has set its Q2 2026 guidance at 2.950-3.050 EPS and its FY 2026 guidance at 14.400-14.600 EPS. As a group, equities analysts expect that Waters Corporation will post 14.5 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. Morgan Stanley dropped their price objective on shares of Waters from $423.00 to $350.00 and set an “equal weight” rating for the company in a research note on Sunday, February 22nd. UBS Group increased their price objective on shares of Waters from $330.00 to $375.00 and gave the company a “neutral” rating in a research note on Wednesday, May 6th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Waters in a research note on Monday, April 20th. TD Cowen raised their price target on shares of Waters from $345.00 to $385.00 and gave the company a “hold” rating in a research note on Wednesday, May 6th. Finally, Guggenheim reaffirmed a “buy” rating and set a $440.00 price target on shares of Waters in a research note on Tuesday, February 10th. Three investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $394.24.

Insider Buying and Selling

In related news, Director Wei Jiang purchased 500 shares of Waters stock in a transaction on Monday, March 16th. The stock was acquired at an average cost of $289.46 per share, for a total transaction of $144,730.00. Following the completion of the acquisition, the director owned 3,441 shares of the company’s stock, valued at $996,031.86. This trade represents a 17.00% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.31% of the company’s stock.

Waters Company Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.